BACKGROUND & AIMS: The immunoinhibitory receptor programmed death-1 (PD-1) is up-regulated on dysfunctional virus-specific CD8 T cells during chronic viral infections, and blockade of PD-1/PD-ligand (PD-L) interactions can restore their function. As hepatitis C virus (HCV) persists in the liver with immune-mediated disease pathogenesis, we examined the role of PD-1/PD-L pathway in antigen-specific CD8 T-cell dysfunction in the liver and blood of HCV-infected patients. METHODS: PD-1 expression and function of circulating CD8 T cells specific for HCV, Epstein-Barr virus, and influenza virus were examined ex vivo and following antigenic stimulation in vitro in patients with acute, chronic, and resolved HCV infection using class I tetramers and flow cytometry. Intrahepatic CD8 T cells were examined from liver explants of chronically HCV-infected transplant recipients. RESULTS: Intrahepatic HCV-specific CD8 T cells from chronically HCV-infected patients were highly PD-1 positive, profoundly dysfunctional, and unexpectedly refractory to PD-1/PD-L blockade, contrasting from circulating PD-1-intermediate HCV-specific CD8 T cells with responsiveness to PD-1/PD-L blockade. This intrahepatic functional impairment was HCV-specific and directly associated with the level of PD-1 expression. Highly PD-1-positive intrahepatic CD8 T cells were more phenotypically exhausted with increased cytotoxic T-lymphocyte antigen 4 and reduced CD28 and CD127 expression, suggesting that active antigen-specific stimulation in the liver induces a profound functional exhaustion not reversible by PD-1/PD-L blockade alone. CONCLUSIONS: HCV-specific CD8 T-cell dysfunction and responsiveness to PD-1/PD-L blockade are defined by their PD-1 expression and compartmentalization. These findings provide new and clinically relevant insight to differential antigen-specific CD8 T-cell exhaustion and their functional restoration.
BACKGROUND & AIMS: The immunoinhibitory receptor programmed death-1 (PD-1) is up-regulated on dysfunctional virus-specific CD8 T cells during chronic viral infections, and blockade of PD-1/PD-ligand (PD-L) interactions can restore their function. As hepatitis C virus (HCV) persists in the liver with immune-mediated disease pathogenesis, we examined the role of PD-1/PD-L pathway in antigen-specific CD8 T-cell dysfunction in the liver and blood of HCV-infectedpatients. METHODS:PD-1 expression and function of circulating CD8 T cells specific for HCV, Epstein-Barr virus, and influenza virus were examined ex vivo and following antigenic stimulation in vitro in patients with acute, chronic, and resolved HCV infection using class I tetramers and flow cytometry. Intrahepatic CD8 T cells were examined from liver explants of chronically HCV-infected transplant recipients. RESULTS: Intrahepatic HCV-specific CD8 T cells from chronically HCV-infectedpatients were highly PD-1 positive, profoundly dysfunctional, and unexpectedly refractory to PD-1/PD-L blockade, contrasting from circulating PD-1-intermediate HCV-specific CD8 T cells with responsiveness to PD-1/PD-L blockade. This intrahepatic functional impairment was HCV-specific and directly associated with the level of PD-1 expression. Highly PD-1-positive intrahepatic CD8 T cells were more phenotypically exhausted with increased cytotoxic T-lymphocyte antigen 4 and reduced CD28 and CD127 expression, suggesting that active antigen-specific stimulation in the liver induces a profound functional exhaustion not reversible by PD-1/PD-L blockade alone. CONCLUSIONS:HCV-specific CD8 T-cell dysfunction and responsiveness to PD-1/PD-L blockade are defined by their PD-1 expression and compartmentalization. These findings provide new and clinically relevant insight to differential antigen-specific CD8 T-cell exhaustion and their functional restoration.
Authors: Lydie Trautmann; Loury Janbazian; Nicolas Chomont; Elias A Said; Sylvain Gimmig; Benoit Bessette; Mohamed-Rachid Boulassel; Eric Delwart; Homero Sepulveda; Robert S Balderas; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sekaly Journal: Nat Med Date: 2006-08-20 Impact factor: 53.440
Authors: Mathis Heydtmann; Debbie Hardie; Philip L Shields; Jeff Faint; Christopher D Buckley; James J Campbell; Michael Salmon; David H Adams Journal: J Immunol Date: 2006-07-01 Impact factor: 5.422
Authors: Henry Radziewicz; Chris C Ibegbu; Marina L Fernandez; Kimberly A Workowski; Kamil Obideen; Mohammad Wehbi; Holly L Hanson; James P Steinberg; David Masopust; E John Wherry; John D Altman; Barry T Rouse; Gordon J Freeman; Rafi Ahmed; Arash Grakoui Journal: J Virol Date: 2006-12-20 Impact factor: 5.103
Authors: Cheryl L Day; Daniel E Kaufmann; Photini Kiepiela; Julia A Brown; Eshia S Moodley; Sharon Reddy; Elizabeth W Mackey; Joseph D Miller; Alasdair J Leslie; Chantal DePierres; Zenele Mncube; Jaikumar Duraiswamy; Baogong Zhu; Quentin Eichbaum; Marcus Altfeld; E John Wherry; Hoosen M Coovadia; Philip J R Goulder; Paul Klenerman; Rafi Ahmed; Gordon J Freeman; Bruce D Walker Journal: Nature Date: 2006-08-20 Impact factor: 49.962
Authors: Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed Journal: Nature Date: 2005-12-28 Impact factor: 49.962
Authors: David E Kaplan; Kazushi Sugimoto; Kimberly Newton; Mary E Valiga; Fusao Ikeda; Ayse Aytaman; Frederick A Nunes; Michael R Lucey; Barbara A Vance; Robert H Vonderheide; K Rajender Reddy; Jane A McKeating; Kyong-Mi Chang Journal: Gastroenterology Date: 2006-11-29 Impact factor: 22.682
Authors: Wen Xiao; Long Feng Jiang; Xiao Zhao Deng; Dan Yan Zhu; Jia Ping Pei; Mao Lei Xu; Bing Jun Li; Chang Jun Wang; Jing Hai Zhang; Qi Zhang; Zhen Xian Zhou; Wei Liang Ding; Xiao Dong Xu; Ming Yue Journal: Immunol Res Date: 2016-04 Impact factor: 2.829
Authors: Cheng J Ma; Lei Ni; Ying Zhang; C L Zhang; Xiao Y Wu; Antwan N Atia; Penny Thayer; Jonathan P Moorman; Zhi Q Yao Journal: Immunology Date: 2010-11-23 Impact factor: 7.397
Authors: K Sumida; S Shimoda; S Iwasaka; S Hisamoto; H Kawanaka; T Akahoshi; T Ikegami; K Shirabe; N Shimono; Y Maehara; C Selmi; M E Gershwin; K Akashi Journal: Clin Exp Immunol Date: 2013-10 Impact factor: 4.330
Authors: Eui-Cheol Shin; Su-Hyung Park; Michelina Nascimbeni; Marian Major; Laura Caggiari; Valli de Re; Stephen M Feinstone; Charles M Rice; Barbara Rehermann Journal: J Virol Date: 2013-02-06 Impact factor: 5.103
Authors: Shawn D Blackburn; Alison Crawford; Haina Shin; Antonio Polley; Gordon J Freeman; E John Wherry Journal: J Virol Date: 2009-12-02 Impact factor: 5.103